For the therapy of nonalcoholic steatohepatitis (NASH), chronic hepatitis B virus (HBV) infection (Wang et al., 2018c), and inflammatory bowel disease (IBD), FXR has provided a novel target. This evidence concerns the gene NR1H4 and metabolic dysfunction-associated steatohepatitis.